- Home
- OIA vs MREO Comparison
OIA vs MREO Comparison
Compare OIA & MREO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | OIA | MREO |
|---|---|---|
| Founded | 1988 | 2015 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Finance Companies | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 287.0M | 324.6M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | OIA | MREO |
|---|---|---|
| Price | $6.16 | $0.47 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $3.90 |
| AVG Volume (30 Days) | 97.9K | ★ 39.0M |
| Earning Date | 01-01-0001 | 11-10-2025 |
| Dividend Yield | ★ 4.88% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $500,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $6,363.05 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $4.93 | $0.20 |
| 52 Week High | $6.72 | $3.26 |
Technical Indicators
Market Signals| Indicator | OIA | MREO |
|---|---|---|
| Relative Strength Index (RSI) | 56.16 | 31.42 |
| Support Level | $6.12 | $0.48 |
| Resistance Level | $6.21 | $0.78 |
| Average True Range (ATR) | 0.06 | 0.09 |
| MACD | 0.00 | 0.04 |
| Stochastic Oscillator | 72.73 | 27.28 |
Price Performance
Historical ComparisonAbout OIA Invesco Municipal Income Opportunities Trust
Invesco Muni Income Opps Trust operates as a diversified closed-end management investment company. Its investment objective is to provide a high level of current income which is exempt from federal income tax.
About MREO Mereo BioPharma Group plc
Mereo BioPharma Group PLC is a United Kingdom (U.K.) based biopharmaceutical company focused on the development of therapeutics for rare diseases. The company has developed a portfolio of late-stage clinical product candidates, and its two rare disease product candidates are setrusumab for the treatment of osteogenesis imperfecta (OI) and alvelestat primarily for the treatment of severe alpha-1 antitrypsin deficiency-associated lung disease (AATD-LD).